1
Sundsmo John S, Ksander George A, Mcpherson John M, Ross Russel, Sprugel Katherine H: Wound healing composition.. Collagen, Univ Washington, October 28, 1987: EP0243179-A1 (44 worldwide citation)

A soft tissue wound healing composition comprising a mixture of fibrillar collagen, heparin, and an effective amount of a growth, chemotactic or differentiation factor, preferably FGF or PDGF in which the factor may be incorporated as synthetic or purified factor or in the form of undegranulated pla ...


2
Glaser Bert M, Pharriss Bruce B, Hanham Ann F, Ksander George A: Method of treating macular degeneration using tgf-$g(b). Celtrix Pharmaceuticals, PARK Freddie K, April 4, 1996: WO/1996/009838 (1 worldwide citation)

This invention is a method for the treatment of macular degeneration, and in particular, age-related macular degeneration. The method entails application of an effective amount of Transforming Grtowth Factor-$g(b) (TGF-$g(b)) to the area of the retina requiring treatment. In one treatment regime, th ...


3
Glaser Bert M, Pharriss Bruce B, Hanham Ann F, Ksander George A: Method of treating ophthalmic disorders using tgf--g(b).. Celtrix Pharma, May 10, 1995: EP0651650-A1

This invention is a method for the treatment of ophthalmic disorders. The method is suitable for treatment of a variety of disorders including macular holes, macular degeneration, and retinal detachment and tears, cataracts, and corneal and scleral injuries. The method entails application of an effe ...


4
Sundsmo John S, Sprugel Katherine H, Ross Russell, Ksander George A, Mcpherson John M: Composition cicatrisante contenant du collagene, Wound healing composition containing collagen. Celtrix Pharmaceuticals, Celtrix Laboratories, University Of Washington, ADE & COMPANY, January 21, 1992: CA1294546

-22-WOUND-HEALING COMPOSITION Abstract A soft tissue wound healing compositioncomprising a mixture of fibrillar collagen, heparin, andan effective amount of a growth, chemotactic ordifferentiation factor, preferably FGF or PDGF in whichthe factor may be incorporated as synthetic or purifiedfactor or ...


5
Glaser Bert M, Pharriss Bruce B, Hanham Ann F, Ksander George A: Method of treating ophthalmic disorders using tgf-$g(b). Celtrix Pharmaceuticals, LUTHER Barbara J, January 20, 1994: WO/1994/001124

This invention is a method for the treatment of ophthalmic disorders. The method is suitable for treatment of a variety of disorders including macular holes, macular degeneration, and retinal detachment and tears, cataracts, and corneal and scleral injuries. The method entails application of an effe ...